Zealand Pharma A/S (ZEAL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Zealand Pharma A/S

    NASDAQ: ZEAL · Real-Time Price · USD
    17.59
    0.00 (0.00%)
    At close: Sep 29, 2022, 10:00 PM

    Zealand Pharma A/S Income Statement

    Financials in DKK. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year Q1 2022 Q3 2021 Q4 2021 Q2 2021 Q1 2021
    Period Ending Mar 10, 2022 Sep 30, 2021 Sep 6, 2021 Jun 30, 2021 Mar 31, 2021
    Revenue
    		 15.08M 106.41M 54.02M 84.33M 47.82M
    Cost of Revenue
    		 2.91M 28.67M 23.84M 42.56M 23.74M
    Gross Profit
    		 12.16M 77.73M 30.18M 41.77M 24.08M
    Operating Income
    		 -302M -211.8M -289.75M -289.92M -260.9M
    Interest Income
    		 n/a n/a n/a n/a n/a
    Pretax Income
    		 -168.96M -195.73M -285.84M -304.31M -241.06M
    Net Income
    		 -181.04M -198.89M -280.26M -296.81M -242.18M
    Selling & General & Admin
    		 85.16M 148.31M 156.31M 182.13M 149.5M
    Research & Development
    		 152.53M 141.3M 162.19M 149.66M 135.31M
    Other Expenses
    		 -112K -73K -751K -99K 164K
    Operating Expenses
    		 237.58M 289.54M 317.75M 331.69M 284.98M
    Interest Expense
    		 18.84M 2.48M -2.27M 1.11M 2.75M
    Selling & Marketing Expenses
    		 34.55M 78.82M 93.58M 120.93M 81.93M
    Cost & Expenses
    		 240.5M 318.21M 341.59M 374.25M 308.72M
    Income Tax Expense
    		 12.08M 3.15M -5.58M -7.49M 1.12M
    Shares Outstanding (Basic)
    		 43.63M 43.15M 43.15M 43.2M 42.15M
    Shares Outstanding (Diluted)
    		 43.63M 43.15M 43.15M 43.2M 42.15M
    EPS (Basic)
    		 -4.15 -4.61 -6.49 -6.87 -5.75
    EPS (Diluted)
    		 -4.15 -4.61 -6.49 -6.87 -5.75
    EBITDA
    		 -191.93M -193.25M -288.1M -303.2M -238.31M
    EBIT
    		 -150.13M -193.25M -288.1M -303.2M -238.31M
    Depreciation & Amortization
    		 110.07M 18.55M 1.64M -13.28M 22.59M

    Add to Watchlist